Sulfatase inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 1, 2013, Pages 79-98

  Williams, Spencer J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aromatase inhibitors; EMATE; Endometriosis; Estrogen dependent breast cancer; Irosustat; Lysosomal storage disorders; PGL2001; Sanfilippo type A; Steroid sulfatase; STX64

Indexed keywords

ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; ESTERASE INHIBITOR; IROSUSTAT; PRASTERONE; PRASTERONE SULFATE; STX140; STX1938; STX213; SULFATASE INHIBITOR; SURVIVIN; TAMOXIFEN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RECURRENCE; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENZYME ACTIVE SITE; HUMAN; HYDROLYSIS; IC 50; LIPID BILAYER; LYSOSOME STORAGE DISEASE; MOLECULAR DOCKING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; PROSTATE CANCER; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVIEW; ROUGH ENDOPLASMIC RETICULUM; SANFILIPPO SYNDROME;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; ENDOMETRIOSIS; ENZYME INHIBITORS; ESTRADIOL; FEMALE; HUMANS; MALE; MUCOPOLYSACCHARIDOSIS III; PATENTS AS TOPIC; PROSTATIC NEOPLASMS; STERYL-SULFATASE; SULFONIC ACIDS;

EID: 84871529359     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.736965     Document Type: Review

References (154)

1. Hanson SR, Best MD, Wong C-H. Sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed 2004;43:5736-63
2. von Figura K, Schmidt B, Selmer T, Dierks T. A novel protein modification generating an aldehyde group in sulfatases: its role in catalysis and disease. Bioessays 1998;20:505-10 (Pubitemid 28320613)
3. Bojarova P, Williams SJ. Sulfotransferases, sulfatases and formylglycine-generating enzymes: a sulfation fascination. Curr Opin Chem Biol 2008;12:573-81
4. Hagelueken G, Adams TM, Wiehlmann L, et al. The crystal structure of SdsA1, an alkylsulfatase from Pseudomonas aeruginosa, defines a third class of sulfatases. Proc Natl Acad Sci USA 2006;103:7631-6
5. Chapman E, Best MD, Hanson SR, Wong C-H. Sulfotransferases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed 2004;43:3526-48
6. Bojarova P, Williams SJ. Aryl sulfamates are broad spectrum inactivators of sulfatases: effects on sulfatases from various sources. Bioorg Med Chem Lett 2009;19:477-80
7. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010;186:113-37
8. Lin SX, Chen J, Mazumdar M, et al. Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol 2010;6:485-93
9. Woo LWL, Purohit A, Potter BVL. Development of steroid sulfatase inhibitors. Mol Cell Endocrinol 2011;340:175-85
10. Barrios C, Forbes JF, Jonat W, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012;23:1378-86
11. Elger W, Barth A, Hedden A, et al. Estrogen sulfamates: a new approach to oral estrogen therapy. Reprod Fertil Dev 2001;13:297-305 (Pubitemid 33133348)
12. Maltais R, Poirier D. Steroid sulfatase inhibitors: a review covering the promising 2000 - 2010 decade. Steroids 2011;76:929-48
13. Nussbaumer P, Billich A. Steroid sulfatase inhibitors. Med Res Rev 2004;24:529-76 (Pubitemid 38802700)
14. Purohit A, Foster PA. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J Endocrinol 2012;212:99-110
15. Poirier D, Ciobanu LC, Maltais R. Steroid sulfatase inhibitors. Expert Opin Ther Patents 1999;9:1-17
16. Horvath A, Billich A. Steroid sulfatase inhibitors. Expert Opin Ther Patents 2005;15:1541-53 (Pubitemid 41671616)
17. Bond CS, Clements PR, Ashby SJ, et al. Structure of a human lysosomal sulfatase. Structure 1997;5:277-89 (Pubitemid 27158733)
18. Lukatela G, Krauss N, Theis K, et al. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. Biochemistry 1998;37:3654-64 (Pubitemid 28162920)
19. Bojarova P, Denehy E, Walker I, et al. Direct evidence for ArO-S bond cleavage upon inactivation of Pseudomonas aeruginosa arylsulfatase by aryl sulfamates. ChemBioChem 2008;9:613-23
20. Hernandez-Guzman FG, Higashiyama T, Pangborn W, et al. Structure of human estrone sulfatase suggests functional roles of membrane association. J Biol Chem 2003;278:22989-97 (Pubitemid 36830364)
21. Boltes I, Czapinska H, Kahnert A, et al. 1.3 A structure of arylsulfatase from Pseudomonas aeruginosa establishes the catalytic mechanism of sulfate ester cleavage in the sulfatase family. Structure 2001;9:483-91 (Pubitemid 32575346)
22. Myette JR, Soundararajan V, Behr J, et al. Heparin/Heparan Sulfate N-Sulfamidase from Flavobacterium heparinum. J Biol Chem 2009;284:35189-200
23. Ghayee H, Auchus R. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Dis 2007;8:289-300
24. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25:947-70 (Pubitemid 39657774)
25. Purohit A, Woo LWL, Potter BVL. Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol 2011;340:154-60
26. Lin A, Mu J, Yang J, Roach PJ. Self-glucosylation of glycogenin, the initiator of glycogen biosynthesis, involves an inter-subunit reaction. Arch Biochem Biophys 1999;363:163-70 (Pubitemid 29394343)
27. Utsumi T, Yoshimura N, Takeuchi S, et al. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res 1999;59:377-81 (Pubitemid 29048871)
28. Colette S, Defrere S, Lousse JC, et al. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. Hum Reprod 2011;26:1362-70
29. Preglem. WO2009037539; 2009
30. Duquesne University of the Holy Ghost. US5763492; 1998
31. Duquesne University of the Holy Ghost. US5556847; 1996
32. Celltech Therapeutics; University College London. WO9526717; 1995
33. Janssen Pharmaceutical. WO03077924; 2003
34. Novartis. WO2006097293; 2006
35. Preglem. WO2010013187; 2010
36. Imperial College of Science, Technology and Medicine. WO9305064; 1993
37. Imperial College of Science, Technology and Medicine. WO9113083; 1991
38. Duquesne University of the Holy Ghost. US5571933; 1996
39. Chander SK, Purohit A, Woo LWL, et al. The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates. Biochem Biophys Res Commun 2004;322:217-22 (Pubitemid 39099257)
40. Woo LWL, Fischer DS, Sharland CM, et al. Anticancer steroid sulfataseinhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography. Mol Cancer Ther 2008;7:2435-44
41. Winum J-Y, Vullo D, Casini A, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 2003;46:2197-204 (Pubitemid 36583498)
42. Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 1994;37:219-21 (Pubitemid 24063038)
43. Purohit A, Williams GJ, Howarth NM, et al. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone- 3-O-sulfamate. Biochemistry 1995;34:11508-14
44. Abbate F, Winum J-Y, Potter BVL, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg Med Chem Lett 2004;14:231-4 (Pubitemid 38016213)
45. Elger W, Schwarz S, Hedden A, et al. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol 1995;55:395-403 (Pubitemid 26022205)
46. Jenapharm. WO0006175; 2000
47. Sterix. US7067503; 2006
48. SRI International. US6046186; 2000
49. Duquesne University of the Holy Ghost; Kyowa Hakko Kogyo Co. US6376687; 2002
50. Duquesne University of the Holy Ghost. US6288050; 2001
51. Ishida H, Nakata T, Suzuki M, et al. A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells in vitro and in animal models. Breast Cancer Res Treat 2007;106:215-27 (Pubitemid 350045018)
52. Ishida H, Sato N, Hosogi J, et al. Inactivation of recombinant human steroid sulfatase by KW-2581. J Steroid Biochem Mol Biol 2008;108:17-22 (Pubitemid 351173815)
53. Ishida H, Nakata T, Sato N, et al. Inhibition of steroid sulfatase activity and cell proliferation in ZR-75-1 and BT-474 human breast cancer cells by KW-2581 in vitro and in vivo. Breast Cancer Res Treat 2007;104:211-19 . A promising candidate for drug development. (Pubitemid 47084225)
54. Imperial College of Science Technology and Medicine. WO9824802; 1998
55. Woo LWL, Leblond B, Purohit A, Potter BVL. Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors. Bioorg Med Chem 2012;20:2506-19
56. Sterix. US6011024; 2000
57. Sterix. US20090221841; 2009
58. Teikoku Hormone Mfg. EP0934949; 1999
59. Imperial College of Science Technology and Medicine; University of Bath. WO9927935; 1999
60. Hejaz HA, Purohit A, Mahon MF, et al. Synthesis and biological activity of the superestrogen (E)-17-oximino-3-Osulfamoyl- 1,3,5(10)-estratriene: X-ray crystal structure of (E)-17-oximino-3- hydroxy-1,3,5(10)-estratriene. J Med Chem 1999;42:3188-92 (Pubitemid 29384056)
61. Sterix. WO0232409; 2002
62. Sterix. WO03033518; 2003
63. Sterix. WO2007099304; 2007
64. Sterix. US20090182000; 2009
65. Fischer DS, Woo LWL, Mahon MF, et al. D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg Med Chem 2003;11:1685-700 (Pubitemid 36349150)
66. Fischer DS, Chander SK, Woo LW, et al. Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. J Steroid Biochem Mol Biol 2003;84:343-9 (Pubitemid 36514849)
67. Foster PA, Chander SK, Parsons MFC, et al. Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res Treat 2008;111:129-38 (Pubitemid 352009238)
68. Numazawa M, Tominaga T, Watari Y, Tada Y. Inhibition of estrone sulfatase by aromatase inhibitor-based estrogen 3-sulfamates. Steroids 2006;71:371-9
69. Schering. WO2004074307; 2004
70. Schering. US6583130; 2003
71. Jenapharm. US5705495; 1998
72. Woo LWL, Purohit A, Reed MJ, Potter BVL. Oestrone 3-O-(N-acetyl) sulphamate, a potential molecular probe of the active site of oestrone sulphatase. Bioorg Med Chem Lett 1997;7:3075-80 (Pubitemid 28009323)
73. Organon. WO0053620; 2000
74. Ciobanu LC, Boivin RP, Luu-The V, et al. Potent inhibition of steroid sulfatase activity by 3-O-sulfamate 17alpha-benzyl(or 4'-tert-butylbenzyl) estra-1,3,5(10)-trienes: combination of two substituents at positions C3 and c17alpha of estradiol. J Med Chem 1999;42:2280-6 (Pubitemid 29284249)
75. Ciobanu LC, Luu-The V, Martel C, et al. Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res 2003;63:6442-6 (Pubitemid 37255194)
76. Poirier D, Boivin RP. 17 alpha-alkyl- or 17alpha-substituted benzyl-17 betaestradiols: a new family of estrone-sulfatase inhibitors. Bioorg Med Chem Lett 1998;8:1891-6 (Pubitemid 28338012)
77. Sterix. WO0216393; 2002
78. Sterix. WO0216394; 2002
79. Leese MP, Leblond B, Newman SP, et al. Anti-cancer activities of novel D-ring modified 2-substituted estrogen- 3-O-sulfamates. J Steroid Biochem Mol Biol 2005;94:239-51 (Pubitemid 40614537)
80. ID Pharma. US6339079; 2002
81. SRI International. WO9832763; 1998
82. SRI International. US5763432; 1998
83. SRI International. US5861388; 1999
84. Hanson SR, Whalen LJ, Wong C-H. Synthesis and evaluation of general mechanism-based inhibitors of sulfatases based on (difluoro)methyl phenyl sulfate and cyclic phenyl sulfamate motifs. Bioorg Med Chem 2006;14:8386-95 (Pubitemid 44667544)
85. Duquesne University of the Holy Ghost. US5567831; 1996
86. Chu GH, Milano S, Kluth L, et al. Structure-activity relationship studies of the amide functionality in (p-Osulfamoyl)- N-alkanoyl tyramines as estrone sulfatase inhibitors. Steroids 1997;62:530-5 (Pubitemid 27319202)
87. Kolli A, Chu GH, Rhodes ME, et al. Development of (p-O-sulfamoyl)-NS. alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors. J Steroid Biochem Mol Biol 1999;68:31-40 (Pubitemid 29130383)
88. Selcer KW, Kabler H, Sarap J, et al. Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells. Steroids 2002;67:821-6 (Pubitemid 35286561)
89. Woo LWL, Purohit A, Reed MJ, Potter BVL. Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. J Med Chem 1996;39:1349-51 (Pubitemid 26112698)
90. Purohit A, Woo LW, Singh A, et al. In vivo activity of 4-methylcoumarin-7-Osulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. Cancer Res 1996;56:4950-5 (Pubitemid 26374434)
91. Imperial College of Science Technology and Medicine; University of Bath. WO9732872; 1997
92. Imperial College of Science Technology and Medicine; University of Bath. WO9730041; 1997
93. Woo LWL, Purohit A, Malini B, et al. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem Biol 2000;7:773-91
94. Woo LWL, Ganeshapillai D, Thomas MP, et al. Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor irosustat (STX64, BN83495). ChemMedChem 2011;6:2019-34
95. Ventura V, Sola J, Celma C, et al. In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification. Drug Metab Dispos 2011;39:1235-46
96. Coombes R, Schmid P, Isambert N, et al. A phase I dose escalation study of steroid sulfatase inhibitor BN83495/ STX64 in postmenopausal women with ER positive breast cancer. Cancer Res 2009;69:abstract 4097
97. Stanway SJ, Purohit A, Woo LWL, et al. Phase I study of STX 64 (667Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006;12:1585-92
98. Novartis. WO9952890; 1999
99. Nussbaumer P, Lehr P, Billich A. 2-Substituted 4-(thio)chromenone 6-Osulfamates: potent inhibitors of human steroid sulfatase. J Med Chem 2002;45:4310-20 (Pubitemid 35025577)
100. Nussbaumer P, Winiski AP, Billich A. Estrogenic potential of 2-alkyl-4-(thio) chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J Med Chem 2003;46:5091-4 (Pubitemid 37352047)
101. Novartis. WO0136398; 2001
102. Schreiner EP, Wolff B, Winiski AP, Billich A. 6-(2-adamantan-2- ylidenehydroxybenzoxazole)- O-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg Med Chem Lett 2003;13:4313-16 (Pubitemid 37492964)
103. Billich A, Meingassner JG, Nussbaumer P, et al. 6-[2- (adamantylidene)-hydroxybenzoxazole]- O-sulfamate, a steroid sulfatase inhibitor for the treatment of androgen- and estrogen-dependent diseases. J Steroid Biochem Mol Biol 2004;92:29-37 (Pubitemid 39486060)
104. Hans-Knoll-Institut. DE19701664; 1998
105. Jutten P, Schumann W, Hartl A, et al. A novel type of nonsteroidal estrone sulfatase inhibitors. Bioorg Med Chem Lett 2002;12:1339-42 (Pubitemid 34454808)
106. Jutten P, Schumann W, Hartl A, et al. Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem 2007;50:3661-6 (Pubitemid 47195471)
107. Novartis. WO03031397; 2003
108. Nussbaumer P, Geyl D, Horvath A, et al. Nortropinyl-arylsulfonylureas as novel, reversible inhibitors of human steroid sulfatase. Bioorg Med Chem Lett 2003;13:3673-7 (Pubitemid 37206484)
109. Lehr P, Billich A, Wolff B, et al. N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase. Bioorg Med Chem Lett 2005;15:1235-8 (Pubitemid 40458680)
110. Lee W, DeRome M, DeBear J, et al. Aryl piperazines: a new class of steroid sulfatase inhibitors for the treatment of hormone-dependent breast cancer. Abstr Pap Am Chem Soc 2003;226:MEDI-301
111. Solvay Pharmaceuticals. US20060281710; 2006
112. Chu GH, Peters A, Selcer KW, Li PK. Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4- hydroxytamoxifen sulfamates. Bioorg Med Chem Lett 1999;9:141-4 (Pubitemid 29059516)
113. Duquesne University of the Holy Ghost; Kyowa Hakko Kogyo Co. US6288107; 2001
114. Rasmussen LM, Zaveri NT, Stenvang J, et al. A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer. Breast Cancer Res Treat 2007;106:191-203 (Pubitemid 350045017)
115. SRI International. US6054446; 2000
116. Rausch L, Green C, Steinmetz K, et al. Preclinical pharmacokinetic, toxicological and biomarker evaluation of SR16157, a novel dual-acting steroid sulfatase inhibitor and selective estrogen receptor modulator. Cancer Chemother Pharmacol 2011;67:1341-52
117. Sterix. US6506792; 2003
118. Woo LW, Sutcliffe OB, Bubert C, et al. First dual aromatase-steroid sulfatase inhibitors. J Med Chem 2003;46:3193-6 (Pubitemid 36842404)
119. Sterix. WO03045925; 2003
120. Sterix. US20070213383; 2007
121. Sterix. US20070213383; 2007
122. Wood PM, Woo LW, Humphreys A, et al. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J Steroid Biochem Mol Biol 2005;94:123-30 (Pubitemid 40614525)
123. Jackson T, Woo LW, Trusselle MN, et al. Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity. Org Biomol Chem 2007;5:2940-52
124. Sterix. WO2005118560; 2005
125. Jackson T, Woo LW, Trusselle MN, et al. Non-steroidal aromatase inhibitors based on a biphenyl scaffold: synthesis, in vitro SAR, and molecular modelling. ChemMedChem 2008;3:603-18
126. Woo LW, Jackson T, Putey A, et al. Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem 2010;53:2155-70
127. Sterix. WO2007068905; 2007
128. Sterix. US20080319037; 2008
129. Sterix. US20100173963; 2010
130. Leese MP, Newman SP, Purohit A, et al. 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents. Bioorg Med Chem Lett 2004;14:3135-8 (Pubitemid 38624578)
131. Leese MP, Hejaz HAM, Mahon MF, et al. A-ring-substituted estrogen-3-Osulfamates: potent multitargeted anticancer agents. J Med Chem 2005;48:5243-56 (Pubitemid 41113911)
132. Sterix. US20040127473; 2004
133. Purohit A, Vernon KA, Wagenaar Hummelinck AE, et al. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J Steroid Biochem Mol Biol 1998;64:269-75 (Pubitemid 28221630)
134. Purohit A, Hejaz HAM, Walden L, et al. The effect of 2-methoxyoestrone-3- Osulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 2000;85:584-9 (Pubitemid 30075140)
135. MacCarthy-Morrogh L, Townsend PA, Purohit A, et al. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 2000;60:5441-50
136. Sterix. US20070225256; 2007
137. Sterix. US20040009959; 2004
138. Jourdan F, Leese MP, Dohle W, et al. Synthesis, antitubulin, and antiproliferative SAR of analogues of 2- methoxyestradiol-3,17-O,O-bis- sulfamate. J Med Chem 2010;53:2942-51
139. Sterix. US8030296; 2011
140. Leese MP, Leblond B, Smith A, et al. 2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 2006;49:7683-96 (Pubitemid 46033660)
141. Foster PA, Newman SP, Leese MP, et al. A new micronized formulation of 2- methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer. Anticancer Res 2008;28:577-81 (Pubitemid 351578896)
142. Foster PA, Ho YT, Newman SP, et al. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. Anticancer Res 2009;29:3751-7
143. Sterix. WO2008117061; 2008
144. Leese MP, Jourdan F, Kimberley MR, et al. Chimeric microtubule disruptors. Chem Commun 2010;46:2907-9
145. Leese MP, Jourdan F, Dohle W, et al. Steroidomimetic tetrahydroisoquinolines for the design of new microtubule disruptors. ACS Med Chem Lett 2012;3:5-9
146. Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009;1:268-79
147. Amicus Therapeutics. 2008
148. Children, Youth and Women's Health Service, Australia. WO2010022461; 2010
149. Frobe C, Simone A, Charig A, Eigen E. Axillary malodour production: a new mechanism. J Soc Cosmet Chem 1990;41:173-85
150. Colgate-Palmolive. US5643559; 1997
151. Colgate-Palmolive. US5676937; 1997
152. Charig A, Froebe C, Simone A, Eigen E. Inhibitor of odor-producing axillary bacterial exozymes. J Soc Cosmet Chem 1991;42:133-45
153. Henkel AG & Co. EP1393518; 2001
154. Palmieri C, Januszewski A, Stanway S, Coombes RC. Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther 2011;11:179-83